Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Perspective Therapeutics Inc CATX

Healthcare Biotechnology
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that... see more

Recent & Breaking News (NYSEAM:CATX)

ISORAY INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates IsoRay, Inc. for Possible Stock Fraud

Business Wire May 21, 2015

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IsoRay, Inc. - ISR

PR Newswire May 21, 2015

A New Exclusive Audio Interview With IsoRay, Inc. CEO Dwight Babcock Is Now Available at Corporate Media Straight Talk.com

Marketwired May 21, 2015

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Law Violations by the Board of IsoRay, Inc.

Business Wire May 21, 2015

EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against IsoRay, Inc. - ISR

Business Wire May 21, 2015

IsoRay's Cesium-131 Lung Cancer Treatment Reports 96% Success in Local Control and 100% Survival at 5 Years in High Risk Patients in Newly Published Report

Marketwired May 20, 2015

IsoRay, Inc. Reports Third Quarter Results

Marketwired May 18, 2015

IsoRay's Cesium-131 Cancer Treatment Takes Center Stage at Weill Cornell's International Symposium "Advances in Brachytherapy"

Marketwired May 11, 2015

Thomas Jefferson University Launches Major Head and Neck Cancer Study Utilizing Cesium-131 Where Current Standard of Care Treatments Have Failed

Marketwired May 7, 2015

IsoRay's Cancer Fighting Isotope Cesium-131 Will Be Featured in Four Oral Presentations at the American Brachytherapy Society (ABS) Convention in Orlando, Florida

Marketwired April 8, 2015

Gynecologic Cancers Successfully Treated Using IsoRay's Cesium-131 Will Be Presented by Dr. Jonathan Feddock Saturday Night While at the Society of Gynecologic Oncology Convention (SGO)

Marketwired March 24, 2015

IsoRay, Inc. Reports Second Quarter Results

Marketwired February 18, 2015

WSA Medical Spotlight

Marketwired February 17, 2015

Shifts In Government Policy Create Potential Surge For Medical Device Leader Pressure Biosciences, Inc (PBIO)

Accesswire February 10, 2015

UPMC Study Reports IsoRay's Cesium-131 Prostate Treatment Provides Strong Cancer Control With Lower Side Effects, Providing Men Improved Quality of Life

Marketwired January 20, 2015

IsoRay's Cesium-131 Therapy Takes Center Stage at Russia's Neftyanik Hospital a Center of Excellence Providing Cutting Edge Cancer Treatments

Marketwired January 13, 2015

IsoRay Ranked 5th Highest Share Price Percentage Gainer (192%) in 2014 Among 2417 Companies Listed on the NYSE Group

Marketwired January 12, 2015

IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer

Marketwired December 8, 2014

IsoRays Cesium-131 Therapy Stops Brain Cancers from Recurring in Treated Locations Where Previous Conventional Treatments Failed

eTeligis December 1, 2014

IsoRay, Inc. Reports First Quarter Results

eTeligis November 17, 2014